scholarly journals Use of Lozenges Containing Lactobacillus brevis CD2 in Recurrent Aphthous Stomatitis: A Double-Blind Placebo-Controlled Trial

Ulcers ◽  
2011 ◽  
Vol 2011 ◽  
pp. 1-6 ◽  
Author(s):  
Vito Trinchieri ◽  
Stefano Di Carlo ◽  
Maurizio Bossu' ◽  
Antonella Polimeni
Keyword(s):  
Controlled Trial ◽  
Clinical Signs ◽  
Signs And Symptoms ◽  
Lactobacillus Brevis ◽  
Recurrent Aphthous Stomatitis ◽  
Aphthous Stomatitis ◽  
Rapid Improvement ◽  
Double Blind ◽  
Rapid Healing ◽  
Clinical Signs And Symptoms

Recurrent aphthous stomatitis is a common disorder of the oral cavity, affecting mainly young people. It is characterized by small ulcers which can be very painful and generally heal spontaneously within 7–14 days. There is currently no therapy that can provide rapid healing. This study evaluated the efficacy and rapidity of response of a lozenge containing Lactobacillus brevis CD2. 30 patients were randomized to take 4 lozenges a day of active product or placebo for 7 days. Signs and symptoms as well as laboratory parameters in the saliva were assessed at the start of the study and after 7 days of treatment. The study demonstrated the efficacy and the rapidity of response of the Lactobacillus brevis CD2 lozenges in resolving the clinical signs and symptoms of aphthous stomatitis, with a significantly rapid improvement of pain. This is the first study confirming the efficacy of a probiotic product in this pathology.

scholarly journals Clinical Efficacy and Safety of Benjakul Remedy Extract for Treating Primary Osteoarthritis of Knee Compared with Diclofenac: Double Blind, Randomized Controlled Trial

2017 ◽  
Vol 2017 ◽  
pp. 1-9
Author(s):  
Patamaporn Rachawat ◽  
Piya Pinsornsak ◽  
Puritat Kanokkangsadal ◽  
Arunporn Itharat
Keyword(s):  
Clinical Efficacy ◽  
Safety Issue ◽  
Controlled Trial ◽  
Clinical Signs ◽  
Signs And Symptoms ◽  
Controlled Study ◽  
Efficacy And Safety ◽  
Double Blind ◽  
Primary Osteoarthritis ◽  
Clinical Signs And Symptoms

Background. The purpose of this study was to investigate the clinical efficacy and safety of Benjakul (BJK) extract for treating primary osteoarthritis (OA) of the knee compared with diclofenac. Methods. A phase 2, double blind, randomized, and controlled study was conducted. The BJK group received 300 mg of BJK extract per day, while another group received 75 mg of diclofenac per day. All patients were followed up at 14 and 28 days. The changing of visual analogue scale (VAS) for pain, 100-meter walking times, the modified Thai WOMAC index scores, and the global assessment were evaluated for efficacy. For safety issue, clinical signs and symptoms, complete physical examination, and renal and liver function were evaluated. Results. 39 and 38 patients for BJK extract group and diclofenac group were evaluated. For efficacy, all patients from both groups reported a decrease in the VAS pain score and 100-meter walking times but only the diclofenac group showed significant reduction of both measurements when compared with day 0. The modified Thai WOMAC scores of both groups were significantly reduced from baseline. However, all efficacy outcomes were not significantly different for both groups. For safety outcomes, the patients from both groups had no severe adverse events reported and only BJK had no toxicity in renal and liver functions. Conclusions. The BJK remedy extract showed equal clinical efficacy in relieving symptoms of OA knee when compared with diclofenac.

Children With Influenza A Infection: Treatment With Rimantadine

PEDIATRICS ◽  
1987 ◽  
Vol 80 (2) ◽  
pp. 275-282
Author(s):  
Caroline Breese Hall ◽  
Raphael Dolin ◽  
Christine L. Gala ◽  
David M. Markovitz ◽  
Yu Qin Zhang ◽  
...  
Keyword(s):  
Influenza A ◽  
Clinical Signs ◽  
Severity Of Illness ◽  
Signs And Symptoms ◽  
Clinical Isolates ◽  
Double Blind Study ◽  
Double Blind ◽  
Viral Shedding ◽  
Development Of Resistance ◽  
Clinical Signs And Symptoms

Treatment with rimantadine of influenza in children and the potential development of resistance in clinical isolates associated with therapy have not been previously studied. We compared rimantadine to acetaminophen therapy in a controlled, double-blind study of 91 children with influenza-like illness. Of 69 children with proven influenza A/H3N2 infection, 37 received rimantadine and 32 received acetaminophen for five days. Children receiving rimantadine showed significantly greater reduction in fever and improvement in daily scores for symptoms and severity of illness during the first three days. Viral shedding also diminished significantly during the first two days but subsequently increased such that by days 6 and 7 the proportion of children shedding virus, as well as the quantity of virus shed, was significantly greater in the rimantadine group. During the seven-day study, of the 22 children in the rimantadine group with serial isolates tested, ten (45.5%) had resistant isolates compared with two (12.5%) of those with serial isolates in the acetaminophen group (P < .03). Thus, of the total 37 children in the rimantadine group, 27% were found to have resistant isolated compared with 6% in the total group receiving acetaminophen (P < .04). Furthermore, the mean inhibitory concentration of rimantadine increased with time in the rimantadine group (r = .4, P = .002) but not in the acetaminophen group. Rimantadine therapy, thus, appears to be significantly more effective than acetaminophen in ameliorating the clinical signs and symptoms of influenza in children. Treatment with rimantadine was also associated with increased viral shedding after the medication was discontinued and with the development of resistance in the clinical isolates, the significance of which is unknown.

scholarly journals Omalizumab for Severe Asthma: Beyond Allergic Asthma

2018 ◽  
Vol 2018 ◽  
pp. 1-10 ◽  
Author(s):  
C. C. Loureiro ◽  
L. Amaral ◽  
J. A. Ferreira ◽  
R. Lima ◽  
C. Pardal ◽  
...  
Keyword(s):  
Allergic Asthma ◽  
Severe Asthma ◽  
Clinical Signs ◽  
Signs And Symptoms ◽  
Allergen Exposure ◽  
Response To Therapy ◽  
Double Blind ◽  
Clinical Signs And Symptoms ◽  
Underlying Mechanisms

Different subsets of asthma patients may be recognized according to the exposure trigger and the frequency and severity of clinical signs and symptoms. Regarding the exposure trigger, generally asthma can be classified as allergic (or atopic) and nonallergic (or nonatopic). Allergic and nonallergic asthma are distinguished by the presence or absence of clinical allergic reaction and in vitro IgE response to specific aeroallergens. The mechanisms of allergic asthma have been extensively studied with major advances in the last two decades. Nonallergic asthma is characterized by its apparent independence from allergen exposure and sensitization and a higher degree of severity, but little is known regarding the underlying mechanisms. Clinically, allergic and nonallergic asthma are virtually indistinguishable in exacerbations, although exacerbation following allergen exposure is typical of allergic asthma. Although they both show several distinct clinical phenotypes and different biomarkers, there are no ideal biomarkers to stratify asthma phenotypes and guide therapy in clinical practice. Nevertheless, some biomarkers may be helpful to select subsets of atopic patients which might benefit from biologic agents, such as omalizumab. Patients with severe asthma, uncontrolled besides optimal treatment, notwithstanding nonatopic, may also benefit from omalizumab therapy, although currently there are no randomized double-blind placebo controlled clinical trials to support this suggestion. However, omalizumab discontinuation according to each patient’s response to therapy and pharmacoeconomical analysis are questions that remain to be answered.

scholarly journals ADD ON EFFECT OF GR̥ ÑJANAKA PĒYA ALONG WITH A THERAPEUTIC DIETARY PROTOCOL IN RAKTĀRŚAḤ (BLEEDING PILE) – A NON-RANDOMIZED CONTROLLED TRIAL

2021 ◽  
Vol 9 (7) ◽  
pp. 1393-1397
Author(s):  
Bindu K.T ◽  
Shobhana M. C. ◽  
Prema P. E
Keyword(s):  
Randomized Controlled Trial ◽  
Controlled Trial ◽  
Clinical Signs ◽  
Signs And Symptoms ◽  
Study Group ◽  
Randomized Controlled ◽  
Therapeutic Protocol ◽  
Before And After ◽  
Clinical Signs And Symptoms

A non-randomized controlled trial was carried out in 40 participants with intervention for 15 days and a follow up of 7 days. Clinical signs and symptoms of raktārśaḥ were assessed before and after the intervention and after fol- lowing up, by using the subjective parameters scale including, Frequency of bleeding, Nature of bleeding, Change in colour of the mucosa of pile mass, Character of defecation and Period of straining. Grñjanaka pēya along with a therapeutic protocol in raktārśaḥ has shown significant positive changes in subjective parameters like frequency of bleeding (p<0.01 level), nature of bleeding (p<0.01 level), changes in the mucosa, period of straining and char- acter of defecation after the 15 days of intervention in the study group. Keywords: Raktārśaḥ, Gr̥ ñjanaka pēya, Therapeutic dietary protocol, Subjective parameters

Sign in / Sign up

Export Citation Format

Share Document